Brainstorm Cell Therapeutics (NASDAQ:BCLI) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a report published on Monday. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, Maxim Group raised shares of Brainstorm Cell Therapeutics from a hold rating to a buy rating and set a $2.00 price objective for the company in a research report on Thursday, July 11th.

Brainstorm Cell Therapeutics Trading Down 2.4 %

BCLI stock opened at $0.33 on Monday. Brainstorm Cell Therapeutics has a 12 month low of $0.13 and a 12 month high of $1.81. The company has a 50-day moving average price of $0.40 and a 200 day moving average price of $0.43. The stock has a market cap of $23.40 million, a PE ratio of -1.04 and a beta of 0.37.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last released its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.02. Sell-side analysts forecast that Brainstorm Cell Therapeutics will post -0.14 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC acquired a new position in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) in the 1st quarter, according to the company in its most recent filing with the SEC. The fund acquired 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned approximately 0.12% of Brainstorm Cell Therapeutics as of its most recent SEC filing. Institutional investors own 14.33% of the company’s stock.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.